• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Why Do So Many Pediatric Antidepressant Research Trials “Fail”?
Research Update

Why Do So Many Pediatric Antidepressant Research Trials “Fail”?

April 1, 2023
Pavan Madan, MD
From The Carlat Child Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Pavan Madan, MD. Dr. Madan has no financial relationships with companies related to this material.

REVIEW OF: Mossman S et al, J Child Adolesc Psychopharmacol 2021;31(4):259–267

STUDY TYPE: Meta-analysis

Many research studies report a 30%–60% placebo response rate in pediatric selective serotonin reuptake inhibitor (SSRI) research, rendering the trial “negative” despite a 55%–60% response from the SSRI. We know that different SSRIs are equally effective in adults with major depressive disorder (MDD), so why does fluoxetine fare better than other SSRIs in pediatric MDD meta-analyses? Is it a true difference or research error? This study explored some of the complex factors that influence research outcomes in children and adolescents with anxiety and depression, and the results can help our patients.

After careful screening, the authors analyzed 49 randomized, double-blinded, placebo-controlled trials of the effectiveness of antidepressants for the treatment of depression or anxiety in youth. They examined demographics, funding sources, disorders targeted, and dosing schedules. More studies received industry funding than federal funding (57% vs 33%), more targeted depression than anxiety (74% vs 27%), and more used flexible dosing than fixed dosing (57% vs 33%). The trials covered 19 antidepressants from five classes, most commonly fluoxetine (κ=7). The mean enrollment was 176 patients per study, and the median treatment duration was eight weeks.

Surprisingly, federally funded antidepressant research trials had a 25% greater chance of showing efficacy as compared to industry-funded trials. While medication response was similar irrespective of funding, industry-funded trials had higher placebo response rates (p<0.001), leading to more frequent trial “failures” despite their incentive to report positive findings (recall the infamous Study 329, where industry researchers misrepresented data to create a treatment effect for paroxetine).

Greater placebo response in industry-funded trials was associated with fewer patients per site and larger numbers of sites. The authors argue that the 1997 FDA Modernization Act and the 2003 Pediatric Research Equity Act prefer research completion over outcomes, thus incentivizing low-quality, underpowered, hastily implemented research studies over higher-quality ones.

Fluoxetine was the only SSRI to have a federally funded study, and the better-quality research design may account for its relative superiority to other SSRIs in children and adolescents. Fluoxetine’s long half-life may be another factor, making it more forgiving with fewer withdrawal problems when there are lapses in compliance.

Carlat Take

Higher placebo rate in pediatric antidepressant trials may be related to poorly designed industry-funded studies, which might be excluded from future meta-analyses to improve accuracy. Step back and deploy a range of lifestyle interventions and therapies, and keep an open mind for trying other medications if fluoxetine fails.

Child Psychiatry Research Update
KEYWORDS antidepressants depression federally funded research fluoxetine industry funded research placebo effect treatment failure
    Pavan Madan, MD

    Dealing With Side Effects of SSRIs

    More from this author
    www.thecarlatreport.com
    Issue Date: April 1, 2023
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Autism in Children and Adolescents, CCPR, April/May/June 2023
    Treating Irritability in Autism: Functional and Medication Approaches
    Addressing Suicidality in Autistic Children and Teens
    Recognizing and Treating Psychosis in Autism
    Autistic Drivers Perform Well
    Testing Neurofeedback for ADHD
    Is It Worth Adding Coenzyme Q10 to Atomoxetine for ADHD?
    Does Treatment of ADHD Help Caregiver Stress?
    Stimulant Treatment Effect on Anxiety in ADHD
    Why Do So Many Pediatric Antidepressant Research Trials “Fail”?
    CME Post-Test, Autism in Children and Adolescents, CCPR, April/May/June 2023
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.